[go: up one dir, main page]

MX2016010662A - Compuestos para mejorar la cognicion y comportamiento social en humanos que tienen trastornos neurologicos. - Google Patents

Compuestos para mejorar la cognicion y comportamiento social en humanos que tienen trastornos neurologicos.

Info

Publication number
MX2016010662A
MX2016010662A MX2016010662A MX2016010662A MX2016010662A MX 2016010662 A MX2016010662 A MX 2016010662A MX 2016010662 A MX2016010662 A MX 2016010662A MX 2016010662 A MX2016010662 A MX 2016010662A MX 2016010662 A MX2016010662 A MX 2016010662A
Authority
MX
Mexico
Prior art keywords
humans
compounds
neurological disorders
social behavior
improving cognition
Prior art date
Application number
MX2016010662A
Other languages
English (en)
Inventor
Shamloo Mehrdad
Yi Bitna
Memar Ardestani Pooneh
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2016010662A publication Critical patent/MX2016010662A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un compuesto de profármaco agonista de ß1-ADR, el cual es hidrolizable in vivo para liberar un compuesto agonista de ß1-ADR, y en el cual el compuesto de profármaco contiene un grupo el cual imparte mayor lipofilicidad y biodisponibilidad al CNS al compuesto de profármaco con relación al compuesto agonista de ß1-ADR.
MX2016010662A 2014-02-18 2015-02-18 Compuestos para mejorar la cognicion y comportamiento social en humanos que tienen trastornos neurologicos. MX2016010662A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461940980P 2014-02-18 2014-02-18
PCT/US2015/016340 WO2015126915A2 (en) 2014-02-18 2015-02-18 Method of improving cognition and social behavior in humans having deficits therein due to neurological disorders and compounds and compositions therefor

Publications (1)

Publication Number Publication Date
MX2016010662A true MX2016010662A (es) 2017-04-27

Family

ID=53879228

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010662A MX2016010662A (es) 2014-02-18 2015-02-18 Compuestos para mejorar la cognicion y comportamiento social en humanos que tienen trastornos neurologicos.

Country Status (8)

Country Link
US (1) US9849134B2 (es)
EP (1) EP3122350A4 (es)
JP (1) JP2017505826A (es)
KR (1) KR20170013856A (es)
CN (1) CN106456649A (es)
CA (1) CA2940059A1 (es)
MX (1) MX2016010662A (es)
WO (1) WO2015126915A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017263657A1 (en) * 2016-05-13 2018-11-29 The Board Of Trustees Of The Leland Stanford Junior University Adrenergic receptor modulating compounds and methods of using the same
CA3161376A1 (en) 2019-12-18 2021-06-24 Anthony P. FORD Methods for improving neurological diseases and disorders
WO2022146045A1 (ko) 2020-12-30 2022-07-07 주식회사 더웨이브톡 항생제 감수성 평가 장치

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0085286B1 (en) * 1981-12-17 1986-04-30 Aktiebolaget Hässle Para-substituted 3-phenoxy-1-carbonylaminoalkylamino-propan-2-ols having beta receptor blocking properties
GB8529885D0 (en) 1985-12-04 1986-01-15 Ici Plc Therapeutic agent
AU2061588A (en) * 1987-09-07 1989-03-09 Imperial Chemical Industries Plc Phenol ester of xamoterol
US6043224A (en) 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
AU2001294808A1 (en) 2000-09-29 2002-04-08 Board Of Trustees Operating Michigan State University Catecholamine pharmaceutical compositions and methods
AU2004220548A1 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US8470546B2 (en) 2008-11-25 2013-06-25 Albert Einstein College Of Medicine Of Yeshiva University Treatment of autism spectrum disorders with agents that activate the Locus Coeruleus-Noradrenergic system
CN105727297A (zh) * 2008-11-28 2016-07-06 诺华股份有限公司 包含hsp90抑制剂和mtor抑制剂的药物组合
US9072730B2 (en) * 2009-05-14 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognitive functions in individuals with down syndrome and/or alzheimer's disease
EP2512470B1 (en) 2009-12-15 2016-11-30 Octeta Therapeutics, LLC Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
WO2015126915A2 (en) 2015-08-27
US9849134B2 (en) 2017-12-26
WO2015126915A3 (en) 2015-11-19
JP2017505826A (ja) 2017-02-23
EP3122350A2 (en) 2017-02-01
KR20170013856A (ko) 2017-02-07
US20160184315A1 (en) 2016-06-30
EP3122350A4 (en) 2018-01-10
CA2940059A1 (en) 2015-08-27
CN106456649A (zh) 2017-02-22

Similar Documents

Publication Publication Date Title
IL289474A (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
IL248546B (en) A multi-fluorinated compound as an inhibitor of proton tyrosine kinase
SG10201809518QA (en) Processes of preparing a jak1 inhibitor and new forms thereto
PL3177659T3 (pl) Zawierające azot związki odpowiednie do wytwarzania poliuretanów
SG11201608764QA (en) Novel disubstituted 1, 2, 4-triazine compound
SV2017005586A (es) Procesos e intermediarios para la preparacion de {1- (etilsulfonil) -3- [4 -(7h -pirrolo [2, 3-d] pirimidin -4- il) -1h -pirazol -1- il] azetidin -3- il} acetonitrilo
IL259617B (en) Methods for the preparation of 3,1-benzodioxole heterocyclic compounds
ZA201608442B (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
ZA201701132B (en) Novel 2,5-substituted pyrimidines as pde inhibitors
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2018003903A (es) Compuesto biciclico y uso del mismo para inhibicion de suv39h2.
IL259556A (en) Solid forms of substituted 6,5-dihydro-6-phenyl-benzo[f]isoquinoline-2-amine compounds
MX2016010662A (es) Compuestos para mejorar la cognicion y comportamiento social en humanos que tienen trastornos neurologicos.
MX2016013439A (es) Formas solidas de un compuesto farmaceuticamente activo.
HK1224305A1 (zh) 用於治療重度低血糖症的新型化合物
GB201714628D0 (en) Production of alkylated compounds
GB201612872D0 (en) Prodrug compounds
AR101951A1 (es) Síntesis de ent-progesterona e intermediarios de la misma
TN2016000181A1 (en) Novel compound for treatment of severe hypoglycemia.
MX2016007984A (es) Nuevo compuesto para el tratamiento de hipoglucemia severa.
MX2015011881A (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
PH12017500492A1 (en) Crystalline bace inhibitors
IL264465B (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
IN2013MU04030A (es)
IN2014MU00069A (es)